Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EHA 2024 | The all-oral regimen of decitabine/cedazuridine, venetoclax, & gilteritinib for older pts with AML

Name: The all-oral regimen of decitabine/cedazuridine, venetoclax, & gilteritinib for older pts with AML
Uploaded: 2024-06-15T00:00:00Z
Duration: 2 min 18 s

Farhad Ravandi • 15 Jun 2024

EHA 2024

Acute Myeloid Leukemia Leukemia Azacitidine Cedazuridine Decitabine Gilteritinib Venetoclax

Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study investigating the all-oral regimen of decitabine/cedazuridine, venetoclax, and gilteritinib for the treatment of older unfit patients with FLT3-mutated acute myeloid leukemia (AML) (NCT05010122). This all-oral regimen has shown promising clinical activity while being convenient and well-tolerated. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.